50
Participants
Start Date
January 31, 2017
Primary Completion Date
October 28, 2020
Study Completion Date
October 28, 2020
Platelet Rich Plasma - Group 1
Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
Corticosteroid Control - Group 2
Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
Wisconsin Institute of Medical Research (WIMR), Madison
Collaborators (1)
DePuy Synthes
INDUSTRY
University of Wisconsin, Madison
OTHER